Ocuphire Pharma Results Presentation Deck

RM 14 Secondary Endpoint: % of Subjects Non-Study Eye Returning to Baseline PD A Similar Significant Effect was Obtained with a Single Drop of Nyxol in the Non-Study Eye Percent of Subjects (%) 100% 80% 60% 40% 20% 0% Placebo (n=91) 2% 2% 0.5 Non-Study Eye (mITT Population) Percent of Subjects Returning to ≤ 0.2 mm of Baseline Nyxol (n=94) p<0.001 6% 1 MIRA-2 Phase 3 Trial 25% p<0.0001 49% 6% 1.5 p<0.0001 51% 10% 2 p<0.0001 68% 14% Source: MIRA-2 TLR table 14.2.1.2 (mITT). Data includes all three mydriatics (Phenylephrine, Tropicamide, Paremyd) 3 Time Post-Treatment with Nyxol/Placebo (Hours) p<0.0001 76% 24% 4 p<0.0001 86% 45% 6 Ocuphire PHARMA

View entire presentation